Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544655 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
- 11
- Study locations
NCT06544655: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
NCT06544655 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 213 participants, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target. The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544655, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Fluorouracil
- DRUG Oxaliplatin
- BIOLOGICAL Nivolumab
- DRUG BMS-986484
Study Locations (11)
Arizona
- University of Arizona Cancer Center - Tucson
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Michigan
- START Midwest - Grand Rapids
South Dakota
- Sanford Cancer Center - Sioux Falls
Texas
- NEXT Oncology - San Antonio
New South Wales
- St Vincent's Hospital - Darlinghurst
South Australia
- Lyell McEwin Hospital - Elizabeth Vale
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-10-14 |
| Phase | Phase 1 |
What NCT06544655 shows while recruiting
NCT06544655 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT06544655 lists 11 locations in 11 states (Arizona, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT06544655 about?
NCT06544655 is a clinical study titled "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors". The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic du...
What is the current status of trial NCT06544655?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2024-10-10. Estimated completion is 2027-10-14.
What conditions does trial NCT06544655 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06544655?
The interventions under investigation include: Capecitabine (DRUG), Fluorouracil (DRUG), Oxaliplatin (DRUG), Nivolumab (BIOLOGICAL), BMS-986484 (DRUG).
Who is sponsoring clinical trial NCT06544655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544655 being conducted?
This trial has 11 study locations across Arizona, California, Michigan, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544655's enrollment target sits among peer trials
213 41st of 144 higher than 104 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI